A Comparative Study for the Evaluation of Two Doses of Ellagic Acid on Hepatic Drug Metabolizing and Antioxidant Enzymes in the Rat

Gurbet Celik,1 Ashi Semiz,1 Serdar Karakurt,2 Sevki Arslan,1 Orhan Adali,2 and Alaattin Sen1,3

1 Department of Biology, Pamukkale University, Kinikli Campus, 20070 Denizli, Turkey
2 Department of Biochemistry, Institute of Natural and Applied Science, Middle East Technical University, 06800 Ankara, Turkey
3 Faculty of Art & Sciences, Biology Department, Pamukkale University, Kinikli, 20070 Denizli, Turkey

Correspondence should be addressed to Alaattin Sen; sena@pau.edu.tr

Received 15 April 2013; Accepted 4 June 2013

Academic Editor: Jason Shearer

Copyright © 2013 Gurbet Celik et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The present study was designed to evaluate different doses of ellagic acid (EA) in vivo in rats for its potential to modulate hepatic phases I, II, and antioxidant enzymes. EA (10 or 30 mg/kg/day, intragastrically) was administered for 14 consecutive days, and activity, protein, and mRNA levels were determined. Although the cytochrome P450 (CYP) 2B and CYP2E enzyme activities were decreased significantly, the activities of all other enzymes were unchanged with the 10 mg/kg/day EA. In addition, western-blot and qRT-PCR results clearly corroborated the above enzyme expressions. On the other hand, while the NAD(P)H:quinone oxidoreductase 1 (NQO1), catalase (CAT), glutathione peroxidase (GPX), and glutathione S-transferase (GST) activities were increased significantly, CYP1A, 2B, 2C, 2E, and 19 enzyme activities were reduced significantly with 30 mg/kg/day EA. In addition, CYP2B, 2C6, 2E1, and 19 protein and mRNA levels were substantially decreased by the 30 mg/kg/day dose of EA, but the CYP1A protein, and mRNA levels were not changed. CYP3A enzyme activity, protein and mRNA levels were not altered by either 10 nor 30 mg/kg/day ellagic acid. These results indicate that EA exerts a dose-dependent impact on the metabolism of chemical carcinogens and drugs by affecting the enzymes involved in xenobiotics activation/detoxification and antioxidant pathways.

1. Introduction

Ellagic acid (EA) is one of the important components of fruits and vegetables [1] and has been shown to possess numerous anticarcinogenic and antimutagenic properties towards various carcinogens [1–7]. Several mechanisms have been proposed to explain the broad antimutagenic and anticarcinogenic effects of EA [8–13]. One of the mechanisms proposed involves inhibition of cytochrome P450 (CYP450) enzymes [8]. CYP450 enzymes are widely known for their role in the metabolism of drugs and other foreign compounds. Thus, modulation of this enzyme system can influence the metabolism of xenobiotics, producing effects of pharmacological and toxicological importance. A number of naturally occurring flavonoids have been shown to modulate the CYP450 system by the activation or inhibition of these enzymes [14]. Multiple P450 isozymes show different substrate specificities and affinities toward both endogenous and exogenous compounds. Among these P450s, CYP1A, 2B, 2C, 2E, and 3A subfamilies have received a great deal of attention in recent years because of their ability to metabolize various pharmaceutical and carcinogenic agents [15–17]. It is well established that CYP1A and CYP2E enzymes are mainly involved in carcinogen metabolism while CYP3A, CYP2B, and CYP2C enzymes are mainly responsible for drug metabolism.

Aromatase represents a crucial enzyme of estrogen biosynthesis, and increased expression of aromatase has been observed in breast cancer tissue [18]. Flavonoids and isoflavones are structurally similar to the endogenous estradiol and possess both estrogenic and antiestrogenic activities.
Another possible mechanism for the broad chemoprotective and antioxidant effects of EA might involve the induction of phase II and antioxidant enzymes. GSTs have a considerably important role in the detoxification of carcinogens [22]. NQO1 prevents quinone redox cycling and lowers levels of electrophilic quinines [23]. Hence, the inductions of GST and NQO1 by flavonoids are possibly associated with cancer chemopreventive effects. The present study is, to our knowledge, the first study analyzing the effect of EA on NQO1 activity, mRNA, and protein levels in rat.

Although there are individual studies examining the effect of EA on several enzymes, no study has evaluated the alteration of so many enzymes simultaneously with different dose of EA. Therefore, the present study was undertaken to observe the overall simultaneous changes following in vivo treatment with different dose of EA by investigating changes in the activity, mRNA, and protein levels of specific rat hepatic enzymes, no study has evaluated the effect of EA on several enzymes, no study has evaluated the alteration of so many enzymes simultaneously with different dose of EA. Therefore, the present study was undertaken to observe the overall simultaneous changes following in vivo treatment with different dose of EA by investigating changes in the activity, mRNA, and protein levels of specific rat hepatic enzymes.

2. Material and Methods

2.1. Chemicals. The following chemicals were purchased from Sigma-Aldrich Chemical Company (St Louis, Missouri, USA): ellagic acid, acrylamide, aniline, anti-rabbit IgG-HRP conjugate, bovine serum albumin (BSA), Folin phenol reagent, glycerol, glycine, HEPES, β-NADPH, phenol, caffeine, TRIS, PMSF, potassium dihydrogen phosphate, dipotassium hydrogen phosphate, sodium dodecyl sulfate (SDS), and sodium potassium tartrate. Anti-rat CYP1A1, CYP2B, CYP2C6, CYP2E1, CYP3A1, and CYP19 antibodies were from Abcam (Abcam PLC, Cambridge, UK). All other chemicals and solvents were obtained from commercial sources at the highest grade of purity available.

2.2. Animals and Treatment. Healthy male Wistar rats, about 12 weeks old and weighing 200–250 g, were obtained from the University Animal House. They were housed in small cages at an ambient temperature of 22 ± 1°C, on a 12 h light/dark cycle, and a standard pellet diet and distilled water were available without restriction. All experimental procedures with the animals were performed under appropriate regimes with veterinary services within the licensed projects (PAUHADEK-2009-007).

After being acclimatized for 1 week, the rats were randomized and divided into three groups. Ellagic acid was given intragastrically to two experimental groups (15 rats per group) in a dose of 10 mg/kg/day (T10) and 30 mg/kg/day (T30) dissolved in DMSO, respectively. Control (15 rats) rats only received a vehicle (DMSO). The doses used were chosen to be similar to the doses used in previous studies in the literature [24–26]. The animals were treated for 14 consecutive days. At the end of the experimental period and following 16 h of fasting, blood was collected by heart puncture and the rats were killed; the livers were removed, rinsed with cold physiological saline, and stored at −80°C until analyzed.

2.3. Preparations of S1.5, Cytosolic, and Microsomal Fraction. Tissues were homogenized in a 4 part homogenization solution (1.15% KCl containing 3 mM EDTA, 0.5 mM APMSF, 0.3 mM e-aminocaproic acid, 0.15 mM butylated hydroxytoluene, and 0.025% Triton X-100) using a tissue homogenizer with a Teflon pestle at 4°C. Subcellular fractions (S1.5, cytosolic, microsomal) of rat tissues were prepared by standard differential centrifugation with calcium aggregation as described by [27]. The amount of protein in individual fractions was measured using BCA [28] with BSA as the standard.

2.4. Enzyme Assays. Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities were determined with an autoanalyzer using audit diagnostics AST and ALT. The microsomal cytochrome P450-dependent aniline 4-hydroxylase (A4H) activities of rat microsomes were determined by measuring the quantity of p-aminophenol formed, as described by [29]. Aminopyrene N-demethylase (APND), ethoxyresorufin O-demethylase (EROD), and methoxyresorufin O-demethylase (EROD), and pentoxyresorufin O-demethylase (PROD) activities were measured according to the method of [30] and modified by [31]. Ethoxyresorufin O-deethylase (EROD), methoxyresorufin O-demethylase (EROD), benzoxoxyresorufin O-demethylase (BROD), pentoxyresorufin O-demethylase (PROD) activities were assayed as described by [15]. Dibenzylfluorescein-O-debenzylase (DBFOD) activities were assayed as described by [32]. Rat liver NQO1 enzyme activity was determined according to the method of [33]. Glutathione S-transferase (GST) activities were assayed as described by [34]. Catalase (CAT) and glutathione peroxidase (GPx) activities were determined by [35, 36], respectively.

2.5. Gel Electrophoresis and Western Blotting. SDS-PAGE and western blotting were performed as described previously [15]. Briefly, 120 μg protein samples were separated on 8.5% polyacrylamide gels using the discontinuous buffer system of [37]. Proteins were transferred to a nitrocellulose membrane by the iBlot dry blotting system (20 V, 12 min), using iBlot gel transfer stacks. Following transfer, the membranes were blocked using 5% nonfat dry milk in TBST (20 mM Tris-HCl, pH 7.4, 400 mM NaCl, and 0.1% (v/v) Tween20) for 60 min, and incubated with mouse polyclonal anti-rat CYP1A1, CYP2B, CYP2C6, CYP2E1, CYP3A1, or CYP19 antibodies (diluted 1:1000 in blocking solution) for 120 min at room temperature. The membranes were then washed with TBST (3 × 5 min), incubated with the secondary antibody (HRP-conjugated anti-rabbit IgG at a 1:5000 or 1:10000 dilution) for 60 min and again washed with TBST (3 × 5 min). Proteins were detected using SuperSignal West Pico Chemoluminescent Substrate (Pierce, Rockford, IL, USA), and bands were visualized and recorded using GelQuant Image Analysis Software in a DNR LightBIS Pro Image Analysis System (DNR Bio-Imaging Systems Ltd., Jerusalem,
**Figure 1:** The expression levels of CYP1A protein and mRNA in control rats and rats treated with EA. Treatments were carried out as described in Section 2. Lanes 1–10, rat liver microsome sample. Wells have equal amount of protein. (a) Representative immunoblot analysis of liver microsomal CYP1A proteins in sample and experimental groups, using rabbit anti-rat CYP1A IgG for 1 h at room temperature. Proteins were detected using chemiluminescent substrate for 3 minutes, and bands were visualized and recorded using a DNR LightBIS Pro Image Analysis System. (b) Comparison of CYP1A protein and mRNA levels among experimental groups. The bar graphs represent the mean intensity of the bands obtained from western blot and/or qRT-PCR results. Results are presented as the mean from three independent experiments and expressed as relative mean ± standard deviation.

**2.6. RNA Isolation and qRT-PCR of CYP mRNAs.** Total RNA was extracted from 100 mg rat livers using TRIzol reagent. Extracted RNA was quantified spectrophotometrically at 260/280 nm, and the integrity was checked using 1% agarose gel. For cDNA synthesis, 2.5 μg of RNA was incubated at 70°C for 10 minutes with 0.5 μg of oligo (dT). After 5 min on ice, 50 U Moloney murine leukemia virus reverse transcriptase, 1 mM dNTPs and 5X reaction buffer were added to the previous mixture and incubated at 42°C for 60 min. The reaction was stopped by heating the mixture to 70°C for 10 min, and the cDNA was stored at −80°C for further use.

qRT-PCR assay was performed by using gene specific primers. The oligosequences used as forward and reverse primers for rat CYP450 isozymes were based on those reported in [38, 39]. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and β-actin were used as a housekeeping gene. The PCR amplification were carried out using Power SYBR Green PCR master mix (Roche Applied Science, Basel, Switzerland) and 500 nmol/L of forward and reverse primers for each gene, for which the final primer concentration was 125 nmol/L each. Quantitative PCR was done using a Light Cycler 1.5 Instrument (Roche Applied Science, Basel, Switzerland). The PCR conditions were as follows: DNA polymerase activation at 95°C for 15 minutes, followed by 45 cycles at 95°C for 10 seconds, 54–57°C annealing (depending on the gene) for 5 seconds, and 72°C for 30 seconds. All gene analyses were done at least three times.

**2.7. Statistical Analysis.** Statistical analyses were performed using the Minitab 13 statistical software package (Minitab, Inc., State College, PA, USA). All results were expressed as means including their Standard Error of Means (SEMs). Comparison between groups was performed using Student's t-test, and P < 0.05 was selected as the level required for statistical significance. Statistical comparisons between three groups were assessed by one-way analysis of variance (ANOVA). When F ratios were significant (P < 0.05), one-way ANOVA was followed by Tukey's Post hoc test for comparisons of multiple group means.

**3. Results**

Control and treated rats showed no significant differences in food consumption or body weight, (data not shown) after intragastric delivery of the EA to the animals at two different doses (T10 and T30).

As shown in Table 1, blood serum AST and ALT activities were not changed when compared to the control rats. As presented in Table 2, hepatic 1A1-associated EROD and 1A2-associated MROD or C3ND activities were decreased 11% and 13% or 40% in T30 treated rats, respectively, when compared to controls.

The effect of the EA on CYP2B-associated BPND, EmND, BROD, and PROD activities is presented in Table 2. EA treatment at T10 or T30 for 14 consecutive days caused a statistically significant (P < 0.05) 13%, 10%, and 15% or 55%, 38%, 23%, and 30% decrease in these activities in the liver, respectively.

CYP2E-associated A4H and NDMA activities in control and EA-treated rats are given in Table 2. As can be seen, A4H activities were not changed when compared to control rats. As presented in Table 2, hepatic 1A1-associated EROD and 1A2-associated MROD or C3ND activities were decreased 11% and 13% or 40% in T30 treated rats, respectively, when compared to controls.

The effect of the EA on CYP2B-associated BPND, EmND, BROD, and PROD activities is presented in Table 2. EA treatment at T10 or T30 for 14 consecutive days caused a statistically significant (P < 0.05) 13%, 10%, and 15% or 55%, 38%, 23%, and 30% decrease in these activities in the liver, respectively.

### Table 1: Blood serum AST and ALT enzyme activities in control and EA-treated rats.

|                | Unit/min/mg protein | Change fold | Unit/min/mg protein | Change fold |
|----------------|---------------------|-------------|---------------------|-------------|
| Control        | 1.53 ± 0.12         | —           | 1.33 ± 0.19         | —           |
| 10 mg/kg EA    | 1.55 ± 0.16         | —           | 1.38 ± 0.21         | —           |
| 30 mg/kg EA    | 1.54 ± 0.21         | —           | 1.34 ± 0.12         | —           |

**Table 1:** Blood serum AST and ALT enzyme activities in control and EA-treated rats.

Control and treated rats showed no significant differences in food consumption or body weight, (data not shown) after intragastric delivery of the EA to the animals at two different doses (T10 and T30).

As shown in Table 1, blood serum AST and ALT activities were not changed when compared to the control rats. As presented in Table 2, hepatic 1A1-associated EROD and 1A2-associated MROD or C3ND activities were decreased 11% and 13% or 40% in T30 treated rats, respectively, when compared to controls.

The effect of the EA on CYP2B-associated BPND, EmND, BROD, and PROD activities is presented in Table 2. EA treatment at T10 or T30 for 14 consecutive days caused a statistically significant (P < 0.05) 13%, 10%, and 15% or 55%, 38%, 23%, and 30% decrease in these activities in the liver, respectively.

CYP2E-associated A4H and NDMA activities in control and EA-treated rats are given in Table 2. As can be seen, A4H activities were not changed when compared to control rats. As presented in Table 2, hepatic 1A1-associated EROD and 1A2-associated MROD or C3ND activities were decreased 11% and 13% or 40% in T30 treated rats, respectively, when compared to controls.

The effect of the EA on CYP2B-associated BPND, EmND, BROD, and PROD activities is presented in Table 2. EA treatment at T10 or T30 for 14 consecutive days caused a statistically significant (P < 0.05) 13%, 10%, and 15% or 55%, 38%, 23%, and 30% decrease in these activities in the liver, respectively.

CYP2E-associated A4H and NDMA activities in control and EA-treated rats are given in Table 2. As can be seen, A4H
Table 2: Changes of activities in liver of EA-treated rats.

| Activity (pmol/min/mg prot.) | Control | 10 mg/kg EA Change (%) | 30 mg/kg EA Change (%) |
|-----------------------------|---------|------------------------|------------------------|
| EROD                        | 6.24 ± 2.23 | 5.58 ± 3.97 [↓] 11 | 6.53 ± 1.52 10         |
| MROD                        | 8.39 ± 2.49 30 | 7.33 ± 3.40 13       | 8.31 ± 1.07 12         |
| C3ND (nmol HCHO/min/mg prot.) | 0.40 ± 0.14 55 | 0.24 ± 1.27 40       | 0.39 ± 0.02 28         |
| EmND (nmol HCHO/min/mg prot.) | 1.96 ± 0.35 49 | 1.22 ± 0.09 38       | 1.78 ± 0.85 26         |
| BPND (nmol HCHO/min/mg prot.) | 1.47 ± 0.40 79 | 0.662 ± 0.308 55     | 1.29 ± 0.61 58         |
| BROD (pmol resorufin/min prot.) | 2.61 ± 0.86 24 | 2.03 ± 1.39 23       | 2.23 ± 1.20 13         |
| PROD (pmol resorufin/min prot.) | 5.61 ± 1.99 26 | 4.60 ± 2.71 30       | 5.89 ± 0.907 20        |
| APND (nmol HCHO/min prot.) | 0.339 ± 0.037 55 | 0.154 ± 0.013 55     | 0.331 ± 0.031 54       |
| A4H (nmol p-aminophenol/min/mg prot.) | 0.344 ± 0.014 194 | 0.145 ± 0.086 58     | 0.245 ± 0.08 28        |
| NDMA (nmol HCHO/min/mg prot.) | 0.405 ± 0.01 42 | 0.114 ± 0.17 56      | 0.298 ± 0.11 26        |
| ERND (nmol HCHO/min/mg prot.) | 0.117 ± 0.027 33 | 0.085 ± 0.045 28     | 0.124 ± 0.021 20       |
| DBFOD (nmol fluorescein/min/mg prot.) | 6.66 ± 0.138 38 | 5.12 ± 1.84 24       | 6.15 ± 0.427 30        |
| NQO1 (nmol/min/mg prot.) | 184 ± 10.25 14 | 541 ± 23.18 94     | 183 ± 9.49 13         |
| GST-CNB (nmol/min/mg prot.) | 559 ± 56.71 64 | 835 ± 13.08 49     | 561 ± 87.11 27         |
| GST-DNB (nmol/min/mg prot.) | 12.99 ± 4.29 42 | 18.45 ± 3.93 13     | 12.90 ± 8.15 26        |
| GST-EA (nmol/min/mg prot.) | 10.35 ± 1.61 33 | 13.79 ± 3.22 33     | 10.32 ± 1.11 20        |
| CAT (nmol/min/mg prot.) | 9.33 ± 0.29 11 | 15.37 ± 0.33 64     | 9.25 ± 0.33 11         |
| GPX (nmol/min/mg prot.) | 0.048 ± 0.004 23 | 0.103 ± 0.003 114   | 0.05 ± 0.007 14        |

*Significantly different from the respective control value, P < 0.05.

and NDMA activities were reduced 58% and 56% with the T30 treatment. Similarly, EA treatment at T10 reduced 28% and 26% with respect to the control.

The effect of the EA on CYP2C6-associated APND, CYP3A-associated ERND, and CYP19-associated DBFOD activity is presented in Table 2. EA treatment at T30 caused a statistically significant 55%, 28%, and 24% decrease in CYP2C6, CYP3A, and CYP19 activities in the liver, respectively.

GSTs activities in control and EA-treated rats are given in Table 2. GST activities towards three different substrates, namely, CDNB, DCNB, and EA were increased 49%, 42%, and 33% (P < 0.05) in the T30 treated group. Furthermore, treatment of rats with T30 dose caused increases of 194%, 64%, and 114% in NQO1, CAT, and GPX activities, respectively, when compared to the control values (Table 2).

The activation of catalytic activities was generally consistent with the protein levels of related CYP isoforms in rat liver microsomes that were prepared from control and EA-treated rats (Figures 1–6). The densitometric scanning of western blot results showed that hepatic CYP1A and CYP3A were not significantly changed in the T10 or T30 treated rats relative to the control animals (Figures 1 and 5).

The densitometric scanning of western blot results showed that hepatic CYP2B protein level was decreased 51% and 38% as a result of two different doses of EA treatments. Moreover, T10 and T30 treatments caused a 53% and 32% reduction of the CYP2E protein level (Figures 2 and 4). Although CYP2C and CYP19 protein levels were reduced with T30 treatment, it was not at a significant level (Figures 3 and 6).

The effect of EA on the mRNA levels of CYP isozymes was also determined throughout this study. The relative CYP1A and CYP3A mRNA levels were not changed significantly in the EA-treated rats as compared to the control animals (Figures 1 and 5). CYP2E level was decreased significantly 79% and 31% in T10 and T30 treated rats, respectively (Figure 4). In addition, CYP2B level was reduced 76% and 39% as a result of two different doses of EA-treated rats relative to the controls (Figure 2). CYP2C level was decreased 49% significantly in EA-treated rats at T30, respectively (Figure 3). Similar to the changes at protein level, CYP19 mRNA was decreased but not significantly (Figure 6).

4. Discussion

Alterations in the cellular metabolism of xenobiotics are the most important mechanisms that play a vital role during chemical-induced carcinogenicity. Therefore, the use of dietary antioxidants is an important preventive method to minimize the pathological and toxic effects associated with xenobiotics [8, 10, 14]. In this context, this study is carried out to examine the dose-dependent effects of EA on specific P450 forms and also on selected phase II and antioxidant enzymes in rat liver.

Plasma AST and ALT, alone or in combination, are primarily recommended for the assessment of hepatocellular injury in rodents and nonrodents in nonclinical studies. They are sensitive markers for drug-induced liver damage, and the elevated activities of these marker enzymes in plasma are indicative of cellular leakage and loss of the functional integrity of cell membranes in the liver [40]. Treatment with EA at different doses (T10 and T30) caused no changes in the activities of these marker enzymes in plasma when compared with the control group. Therefore, EA, at these doses, can be used in preventive or complementary medicine with safety precautions and within the scope of the methods employed in public health.
Among all cytochrome P450 isoforms, CYP1A holds priority due to its role in the metabolism of carcinogens, mutagens, and environmental pollutants. This CYP is the primary P450 involved in the conversion of outstanding carcinogens to the electrophilic metabolites and is known to be induced by its substrates such as benzopyrene. In this study, CYP1A1/CYP1A2-associated enzyme activities, EROD, MROD, and C3ND were all decreased as a result of T30 treatment, consistent with the previous findings of [41]. Although EA treatment resulted in a significant reduction in CYP1A1/CYP1A2-associated enzyme activities, hepatic CYP1A1 protein and mRNA levels were found not to be changed with EA treatments. EA inhibited CYP1A enzymes directly, without an alteration of its gene and protein expression, and the in vivo effect depends to a great degree on the concentration of this compound in rat liver. Hence, the results have demonstrated that EA is able to abrogate chemical carcinogenicity most likely by offsetting CYP1A activity and possibly by the scavenging of the electrophilic metabolite.

CYP2E1 is important in the field of toxicology and carcinogenesis, and it also has a role in drug metabolism [42]. It also plays a vital role in the generation of oxidative stress during alcohol-induced toxicity [43]. Intake of the EA both at doses, T10 and T30, for 14 consecutive days decreased A4H and NDMA activities in the liver. In addition, densitometric analysis of western blots showed that the hepatic CYP2E1 protein level was decreased significantly in the EA-treated rats relative to the control animals. Similarly, [44] showed
that EA has an inhibitory effect on NDMA. Consistent with protein levels, administration of the EA had also decreased the CYP2E1 mRNA level. Since the regulation of CYP2E1 expression is complex, involving transcriptional, posttranscriptional, and posttranslational events with polymorphism playing a role [45], the observed mRNA decrease resulting from EA treatment could be either transcriptional or posttranscriptional, which remains to be elucidated. Hence, no matter what the mechanism is, EA administration might decrease the carcinogenesis by inhibiting CYP2E1 and reduce reactive oxygen species by affecting the metabolic pathways of alcohol.

Cytochrome 2B, 2C, and 3A enzymes participate in a wide array of metabolism of drugs. Treatment with the EA caused a significant decrease in CYP2B-associated EmND, BPND, BROD, and PROD activities as well as CYP2B protein and mRNA. Moreover, CYP2C2-associated APND activity was decreased significantly with T30 dose of EA. Also, CYP2C protein and mRNA level were decreased with the same dose. Similarly, EA-treated mice caused inhibitory effect in CYP3A-associated ERND activity in rat liver microsomes. As previously shown with CYP3A or CYP2C activities [46, 47], EA, which is an antioxidant found in large quantities in pomegranate juice, displayed a probably nonmechanism-based inhibitory effect for CYP3A and CYP2C activities in rat liver microsomes. Thus, drug interactions are fairly likely to occur if EA supplements are taken simultaneously with drugs.

The aromatase enzyme, which converts androgen to estrogen, plays a key role particularly in breast carcinogenesis. CYP19-associated enzyme activities, DBFOD, were decreased.
In this study, EA treatment caused an increase in GSTs, which is possibly associated with cancer chemopreventive effects. Hence, the induction of these enzyme activities by flavonoids such as genistein, daidzein, flavone, rutin, quercitin, myricetin, and kaempferol was reported in recent studies [52–56]. These observations may be of importance in view of the potential use of EA both as potent anticancer agents as well as chemopreventive agents.

5. Conclusion

In this study, the different doses of EA did not produce the same effects. While the lower dose of EA (10 mg/kg/day) was not effective because its concentration might not have been enough to reach the site of action and quench all free radicals generated, the higher dose of EA (30 mg/kg/day) was good enough to be effective. In conclusion, the dose-dependent suppression of CYP1A, CYP2E, and CYP19 and the induction of GSTs, NQO1, GPX, and CAT enzymes suggest anticancer as well as chemopreventive roles for EA while reductions in CYP2B, 2C, and 3A explain potential drug interactions.

Acknowledgments

This work was supported by the Scientific and Technological Research Council of Turkey [109R012] and Pamukkale University [2010FBE081]. Preliminary results reported here were presented at the 36th FEBS in Torino, Italy on June 25-30, 2011.

References

[1] E. M. Daniel, A. S. Krupnick, Y.-H. Heur, J. A. Blinzler, R. W. Nims, and G. D. Stoner, “Extraction, stability, and quantitation of ellagic acid in various fruits and nuts,” Journal of Food Composition and Analysis, vol. 2, no. 4, pp. 338–349, 1989.

[2] H. Mukhtar, M. Das, and D. R. Bickers, “Inhibition of 3-methylcholanthrene-induced skin tumorigenesis in BALB/c mice by chronic oral feeding of trace amounts of ellagic acid in drinking water,” Cancer Research, vol. 46, no. 5, pp. 2262–2265, 1986.

[3] S. Mandal, A. Ahuja, N. M. Shivapurkar, S. J. Cheng, J. D. Groopman, and G. D. Stoner, “Inhibition of aflatoxin Bi mutagenesis in Salmonella typhimurium and DNA damage in cultured rat and human tracheobronchial tissues by ellagic acid,” Carcinogenesis, vol. 8, no. 11, pp. 1651–1656, 1987.

[4] R. Dixit and B. Gold, “Inhibition of N-methyl-N-nitrosourea-induced mutagenicity and DNA methylation by ellagic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 83, no. 21, pp. 8039–8043, 1986.

[5] C. V. Rao, K. Tokumo, J. Rigotty, E. Zang, G. Kelloff, and B. S. Reddy, “Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16x-fluoro-5-androsten-17-one, and ellagic acid individually and in combination,” Cancer Research, vol. 51, no. 17, pp. 4528–4534, 1991.

[6] M. Boukharta, G. Jalbert, and A. Castonguay, “Biodistribution of ellagic acid and dose-related inhibition of lung tumorigenesis in A/J mice,” Nutrition and Cancer, vol. 18, no. 2, pp. 181–189, 1992.
[7] P. Lesca, “Protective effects of ellagic acid and other plant phenols on benzo[a]pyrene-induced neoplasia in mice,” Carcinogenesis, vol. 4, no. 12, pp. 1651–1653, 1983.

[8] M. Das, D. R. Bickers, and H. Mukhtar, “Effect of ellagic acid on hepatic and pulmonary xenobiotic metabolism in mice: studies on the mechanism of its anticarcinogenic action,” Carcinogenesis, vol. 6, no. 10, pp. 1409–1413, 1985.

[9] A. W. Wood, M. T. Huang, and R. L. Chang, “Inhibition of the mutagenicity of bay-region diol epoxides of polycyclic aromatic hydrocarbons by naturally occurring plant phenols: exceptional activity of ellagic acid,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, no. 18, pp. 5513–5517, 1982.

[10] S. Majid, K. L. Khanduja, R. K. Gandhi, S. Kapur, and R. R. Sharma, “Influence of ellagic acid on antioxidant defense system and lipid peroxidation in mice,” Biochemical Pharmacology, vol. 42, no. 7, pp. 1441–1445, 1991.

[11] D. H. Barch and C. C. Fox, “Selective inhibition of methyl-benzyl-nitrosamine-induced formation of esophageal 66-methyl-guanine by dietary ellagic acid in rats,” Cancer Research, vol. 48, no. 24, pp. 7088–7092, 1988.

[12] H. Mukhtar, B. J. Del Tito Jr., and C. L. Marcelo, “Ellagic acid: a potent naturally occurring inhibitor of benzo[a]pyrene metabolism and its subsequent glucuronidation, sulfation and covalent binding to DNA in cultured BALB/c mouse keratinocytes,” Carcinogenesis, vol. 5, no. 12, pp. 1565–1571, 1984.

[13] H. U. Gali, E. M. Perchellet, and J.-P. Perchellet, “Inhibition of tumor promoter-induced ornithine decarboxylase activity by tannic acid and other polyphenols in mouse epidermis in vivo,” Cancer Research, vol. 51, no. 11, pp. 2820–2825, 1991.

[14] A. W. Wood, D. S. Smith, R. L. Chang, M. T. Huang, and A. H. Conney, “Effects of flavonoids on the metabolism of xenobiotics,” Progress in Clinical and Biological Research, vol. 213, pp. 195–210, 1986.

[15] A. Sen and E. Arinc, “Preparation of highly purified cytochrome P450IA1 from leaping mullet (Liza saliens) liver microsomes and its biocatalytic, molecular and immunochemical properties,” Comparative Biochemistry and Physiology C, vol. 121, no. 1–3, pp. 249–265, 1998.

[16] W.-G. Chung, A. Sen, J.-L. Wang-Buhler et al., “cDNA-directed expression of a functional zebrafish CYPIA in yeast,” Aquatic Toxicology, vol. 70, no. 2, pp. 111–121, 2004.

[17] L. Zou, M. R. Harkey, and G. L. Henderson, “Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity,” Life Sciences, vol. 71, no. 13, pp. 1579–1589, 2002.

[18] W. R. Miller, T. J. Anderson, and W. J. L. Jack, “Relationship between tumour aromatase activity, tumour characteristics and response to therapy,” Journal of Steroid Biochemistry and Molecular Biology, vol. 37, no. 6, pp. 1055–1059, 1990.

[19] R. W. Brueggemeier, J. A. Richards, S. Joomprabutra, A. S. Bhat, and J. L. Whetstone, “Molecular pharmacology of aromatase and its regulation by endogenous and exogenous agents,” Journal of Steroid Biochemistry and Molecular Biology, vol. 79, no. 1–5, pp. 75–84, 2001.

[20] L. S. Adams, Y. Zhang, N. P. Seeram, D. Heber, and S. Chen, “Pomegranate ellagitannin-derived compounds exhibit anti-inflammatory and antiaromatase activity in breast cancer cells in vitro,” Cancer Prevention Research, vol. 3, no. 1, pp. 108–113, 2010.

[21] A. Rocha, L. Wang, M. Penichet, and M. Martins-Green, “Pomegranate juice and specific components inhibit cell and molecular processes critical for metastasis of breast cancer,” Breast Cancer Research and Treatment, vol. 136, pp. 647–658, 2012.

[22] J. D. Hayes and D. J. Pulford, “The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance,” Critical Reviews in Biochemistry and Molecular Biology, vol. 30, no. 6, pp. 445–600, 1995.

[23] V. P. Kelly, E. M. Ellis, M. M. Manson et al., “Chemoprevention of aflatoxin B1 hepatocarcinogenesis by coumarin, a natural benzopyrone that is a potent inducer of aflatoxin B1-aldehyde reductase, the glutathione S-transferase A5 and PI subunits, and NAD(P)H:Quinone oxidoreductase in rat liver,” Cancer Research, vol. 60, no. 4, pp. 957–969, 2000.

[24] N. Devipriya, A. R. Sudheer, and V. P. Menon, “Dose-response effect of ellagic acid on circulatory antioxidants and lipids during alcohol-induced toxicity in experimental rats,” Fundamental and Clinical Pharmacology, vol. 21, no. 6, pp. 621–630, 2007.

[25] N. A. El-Boghdady, “Protective effect of ellagic acid and pumpkin seed oil against methotrexate-induced small intestine damage in rats,” Indian Journal of Biochemistry and Biophysics, vol. 48, no. 6, pp. 380–387, 2011.

[26] M. A. Rosillo, M. Sanchez-Hidalgo, A. Cardeno et al., “Dietary supplementation of an ellagic acid-enriched pomegranate extract attenuates chronic colonic inflammation in rats,” Pharmacological Research, vol. 66, pp. 235–242, 2012.

[27] A. Sen and A. Kirikbakan, "Biochemical characterization and distribution of glutathione S-transferases in leaping mullet (Liza saliens)," Biochemistry, vol. 69, no. 9, pp. 993–1000, 2004.

[28] P. K. Smith, R. I. Krohn, G. T. Hermanson et al., "Measurement of protein using bichinchoninic acid," Analytical Biochemistry, vol. 150, no. 1, pp. 76–85, 1985.

[29] Y. Imai, A. Ito, and R. Sato, “Evidence for biochemically different types of vesicles in the hepatic microsomal fraction,” Journal of Biochemistry, vol. 60, no. 4, pp. 417–428, 1966.

[30] T. Nash, “The colorimetric estimation of formaldehyde by means of the Hantzsch reaction,” The Biochemical Journal, vol. 55, no. 3, pp. 416–421, 1953.

[31] J. Cochin and J. Axelrod, “Biochemical and pharmacological changes in the rat following chronic administration of morphine nalorphine and normorphine,” Journal of Pharmacology and Experimental Therapeutics, vol. 125, pp. 105–110, 1959.

[32] L. Kragie, S. D. Turner, C. J. Patten, C. L. Crespi, and D. M. Stresner, “Assessing pregnancy risks of azole antifungals using a high throughput aromatase inhibition assay,” Endocrine Research, vol. 28, no. 3, pp. 129–140, 2002.

[33] J. E. Engstrom, “[56] DT diaphorase,” in Methods in Enzymology, R. W. Estabrook and M. E. Pullman, Eds., vol. 10, pp. 309–317, Academic Press, 1967.

[34] W. H. Habig, M. J. Pabst, and W. B. Jakoby, “Glutathione S-transferases. The first enzymatic step in mercapturic acid formation,” Journal of Biological Chemistry, vol. 249, no. 22, pp. 7130–7139, 1974.

[35] H. Aebi, “Catalase,” in Methods in Enzymatic Analysis, H. V. Bergmeyer, Ed., pp. 673–684, Academic Press, New York, NY, USA, 2nd edition, 1974.

[36] D. E. Paglia and W. N. Valentine, “Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase,” The Journal of Laboratory and Clinical Medicine, vol. 70, no. 1, pp. 158–169, 1967.
[37] U. K. Laemmli, “Cleavage of structural proteins during the assembly of the head of bacteriophage T4,” Nature, vol. 227, no. 5259, pp. 680–685, 1970.

[38] A.-L. Minn, H. Pelczar, C. Denizot et al., “Characterization of microsomal cytochrome P450-dependent monooxygenases in the rat olfactory mucosa,” Drug Metabolism and Disposition, vol. 33, no. 8, pp. 1229–1237, 2005.

[39] H. H. Agus, P. Tekin, M. Bayav, A. Semiz, and A. Sen, “Drug interaction potential of the seed extract of Urtica urens L. (dwarf nettle),” Phytotherapy Research, vol. 23, no. 12, pp. 1763–1770, 2009.

[40] E. G. Giannini, R. Testa, and V. Savarino, “Liver enzyme alteration: a guide for clinicians,” Canadian Medical Association Journal, vol. 172, no. 3, pp. 367–379, 2005.

[41] D. H. Barch, L. M. Rundhaugen, P. E. Thomas, and P. Kardos, “Dietary ellagic acid inhibits the enzymatic activity of CYP1A1 without altering hepatic concentrations of CYP1A1 or CYP1A1 mRNA,” Biochemical and Biophysical Research Communications, vol. 201, no. 3, pp. 1477–1482, 1994.

[42] F. P. Guengerich, D.-H. Kim, and M. Iwasaki, “Role of human cytochrome P-450IIE1 in the oxidation of many low molecular weight cancer suspects,” Chemical Research in Toxicology, vol. 4, no. 2, pp. 168–179, 1991.

[43] D. R. Koop, “Alcohol metabolism’s damaging effects on the cell: a focus on reactive oxygen generation by the enzyme cytochrome P450 2EI,” Alcohol Research and Health, vol. 29, no. 4, pp. 274–280, 2006.

[44] T. Wilson, M. J. Lewis, K. L. Cha, and B. Gold, “The effect of ellagic acid on xenobiotic metabolism by cytochrome P-450IIE1 and nitrosodimethylamine mutagenicity,” Cancer Letters, vol. 61, no. 2, pp. 129–134, 1992.

[45] B. J. Song, “Gene structure and multiple regulations of the ethanol-inducible cytochrome P-450 2EI (CYP2EI) subfamily,” in Alcohol and Hormones, R. R. Watson, Ed., pp. 177–192, Totowa Humana Press, 1994.

[46] D. Farkas, L. E. Oleson, Y. Zhao et al., “Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice,” Journal of Clinical Pharmacology, vol. 47, no. 3, pp. 286–294, 2007.

[47] M. Hidaka, K.-I. Fujita, T. Ogikubo et al., “Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity,” Drug Metabolism and Disposition, vol. 32, no. 6, pp. 581–583, 2004.

[48] S. Ramos, “Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways,” Molecular Nutrition and Food Research, vol. 52, no. 5, pp. 507–526, 2008.

[49] M.-H. Pan and C.-T. Ho, “Chemopreventive effects of natural dietary compounds on cancer development,” Chemical Society Reviews, vol. 37, no. 11, pp. 2558–2574, 2008.

[50] D. Vauzour, A. Rodriguez-Mateos, G. Corona, M. J. Oruna-Concha, and J. P. E. Spencer, “Polyphenols and human health: prevention of disease and mechanisms of action,” Nutrients, vol. 2, no. 11, pp. 1106–1131, 2010.

[51] Y.-J. Suh and H.-K. Na, “NF-κB and Nrf2 as prime molecular targets for chemoprevention and cytoprotection with anti-inflammatory and antioxidant phytochemicals,” Genes and Nutrition, vol. 2, no. 4, pp. 313–317, 2008.

[52] P. J. Ansell, C. Espinosa-Nicholas, E. M. Curran et al., “In vitro and in vivo regulation of antioxidant response element-dependent gene expression by estrogens,” Endocrinology, vol. 145, no. 1, pp. 311–317, 2004.